Highlights United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-11 EDT			5-day change	1st Jan Change
346.19 ^USD	+1.09%		-2.03%	+57.44%

09-05	Transcript : United Therapeutics Corporation Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 08:00 AM
09-04	United Therapeutics Insider Sold Shares Worth $2,821,050, According to a Recent SEC Filing	MT

Highlights

Liquidia Seeks Stay on FDA Exclusivity Approval of Rival Version of Hypertension Drug	08-28	MT
Oppenheimer Raises United Therapeutics Price Target to $575 From $400, Maintains Outperform Rating	08-28	MT
Liquidia Files Legal Challenge Against FDA Decision to Grant 3-Year New Clinical Investigation Exclusivity to Tyvaso DPI	08-22	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	08-19	MT
Top Midday Decliners	08-19	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	08-19	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	08-19	MT
Sector Update: Health Care	08-19	MT
Liquidia's Hypertension Treatment Gains Tentative FDA Approval	08-19	MT
United Therapeutics' Q2 Net Income, Revenue Increase	07-31	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q2 Revenue $714.9M, vs. Street Est of $690.9M	07-31	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.	07-31	CI
United Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-31	CI
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis	07-10	CI
United Therapeutics Corporation's Equity Buyback announced on March 25, 2024, has closed with 3,456,971 shares, representing 7.37% for $1,000 million.	06-29	CI
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension	06-25	MT
Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension	06-25	CI
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction	06-03	MT
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell	05-01	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M	05-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights United Therapeutics Corporation

Equities

UTHR

US91307C1027

Highlights

Filters